Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist.

ABSTRACT:

Background

CMP-001, also known as vidutolimod, is a virus-like particle containing a TLR9 agonist that is showing promise in early clinical trials. Our group previously demonstrated that the immunostimulatory effects of CMP-001 are dependent on an anti-Qβ antibody response which results in opsonization of CMP-001 and uptake by plasmacytoid dendritic cells (pDCs) that then produce interferon (IFN)-α. IFN-α then leads to an antitumor T-cell response that is responsible for the in vivo efficacy of CMP-001. Here, we explore mechanisms by which the initial effects of CMP-001 on pDCs activate other cells that can contribute to development of an antitumor T-cell response.

Methods

Uptake of CMP-001 by various peripheral blood mononuclear cell (PBMC) populations and response to anti-

SUBMITTER: Sabree SA 

PROVIDER: S-EPMC8183212 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature